- Liquidia press release (LQDA): Q1 GAAP EPS of $0.52 beats by $0.11.
- Revenue of $132.87M (+4158.7% Y/Y) beats by $13.47M.
- YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $130 million in the first quarter of 2026.
- More than 4,500 unique
Liquidia GAAP EPS of $0.52 beats by $0.11, revenue of $132.87M beats by $13.47M
